Merck Serono signed two deals in the areas of HIV-related lipodystrophy with Theratechnologies and with Lpath for monoclonal antibodies to treat cancer. The German group, Merck KGaA, has been realigning its business since the purchase of Serono to focus on research-driven pharmaceuticals and biotech products.